These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11068696)

  • 1. RSD requirement for different sample size for blend sampling.
    Saranadasa H
    Drug Dev Ind Pharm; 2000 Nov; 26(11):1213-6. PubMed ID: 11068696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of blend uniformity and content uniformity based on 2003 stratified sampling guidance and 1999 blend uniformity analysis guidance: product A.
    Howard-Sparks M; Gawlikowski A;
    PDA J Pharm Sci Technol; 2004; 58(4):222-30. PubMed ID: 15368992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An approximate approach to sampling size determination for the equivalence hypothesis.
    Hsieh CY; Liu JP
    J Biopharm Stat; 2013 May; 23(3):526-38. PubMed ID: 23611193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of stratefied sampling of blend and dosage units to demonstrate adequacy of mix for powder blends.
    Boehm G; Clark J; Dietrick J; Foust L; Garcia T; Gavini M; Gelber L; Geoffroy JM; Hoblitzell J; Jimenez P; Mergen G; Muzzio F; Planchard J; Prescott J; Timmermans J; Takiar N
    PDA J Pharm Sci Technol; 2003; 57(2):64-74. PubMed ID: 14674508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot trial for the assessment of relative bioavailability in generic drug product development: statistical power.
    Wang Y; Zhou S
    J Biopharm Stat; 1999 Mar; 9(1):179-87. PubMed ID: 10091917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of antiretroviral and opportunistic infection medications dispensed from developing countries and Internet pharmacies.
    Wang T; Hoag SW; Eng ML; Polli J; Pandit NS
    J Clin Pharm Ther; 2015 Feb; 40(1):68-75. PubMed ID: 25381836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose Uniformity of Scored and Unscored Tablets: Application of the FDA Tablet Scoring Guidance for Industry.
    Ciavarella AB; Khan MA; Gupta A; Faustino PJ
    PDA J Pharm Sci Technol; 2016 11/12; 70(6):523-532. PubMed ID: 27974592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of drug content and weight uniformity for half-tablets of 6 commonly split medications.
    Hill SW; Varker AS; Karlage K; Myrdal PB
    J Manag Care Pharm; 2009 Apr; 15(3):253-61. PubMed ID: 19326956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Content uniformity acceptance limit for a validation batch--suppositories, transdermal systems, and inhalations.
    Senderak ET
    Drug Dev Ind Pharm; 2009 Jun; 35(6):735-7. PubMed ID: 19514989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Particle size and content uniformity.
    Yalkowsky SH; Bolton S
    Pharm Res; 1990 Sep; 7(9):962-6. PubMed ID: 2235898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Particle size limits to meet USP content uniformity criteria for tablets and capsules.
    Rohrs BR; Amidon GE; Meury RH; Secreast PJ; King HM; Skoug CJ
    J Pharm Sci; 2006 May; 95(5):1049-59. PubMed ID: 16552749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric Mini-Tablets: Predicting the Hidden Risk of Fill Errors.
    Gerberich BG; Okoh GA; DiNunzio JC; Lowinger MB
    Pharmaceutics; 2023 Feb; 15(2):. PubMed ID: 36839916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impurities in generic pharmaceutical development.
    Kovaleski J; Kraut B; Mattiuz A; Giangiulio M; Brobst G; Cagno W; Kulkarni P; Rauch T
    Adv Drug Deliv Rev; 2007 Jan; 59(1):56-63. PubMed ID: 17196702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical evaluation of the scaled criterion for drug interchangeability.
    Li J; Chow SC
    J Biopharm Stat; 2017; 27(2):282-292. PubMed ID: 27937059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency estimator for assessing of follow-on biologics.
    Lu Y; Zhang ZZ; Chow SC
    J Biopharm Stat; 2014; 24(6):1280-97. PubMed ID: 25072640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In the blood: proposed new requirements for registering generic drugs.
    Senn S
    Lancet; 1998 Jul; 352(9122):85-6. PubMed ID: 9672271
    [No Abstract]   [Full Text] [Related]  

  • 18. [How different can generic drugs be?].
    Skovlund E
    Tidsskr Nor Laegeforen; 2019 Nov; 139(16):. PubMed ID: 31686489
    [No Abstract]   [Full Text] [Related]  

  • 19. Particle Size Limits to Pass the Acceptance Value (AV)-Based USP Content Uniformity Test for Tablets.
    Lou H; Hageman MJ
    J Pharm Sci; 2021 Oct; 110(10):3527-3534. PubMed ID: 34302841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inferential procedure for the probability of passing the USP dissolution test.
    Chiang C; Chen CF; Huang MY; Liu JP
    Pharm Stat; 2012; 11(1):32-8. PubMed ID: 21506255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.